Rapt Therapeutics (NASDAQ:RAPT), Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of precision therapies that harness insights into mTOR biology and chemokine receptor modulation. The company’s proprietary platform is designed to produce next-generation mTORC1 inhibitors that selectively target disease pathways involved in immune-mediated and age-related conditions, while minimizing off-target effects on normal metabolism. Through a deep understanding of molecular signaling and structure-based drug design, Rapt seeks to address unmet medical needs across a spectrum of inflammatory and immuno-oncology indications.
Among its lead development candidates, Rapt is advancing RPT193, a potent and selective CCR4 antagonist in Phase 1/2 clinical studies for atopic dermatitis, as well as RPT503, a CCR8 antagonist for potential use in both inflammatory skin disorders and solid tumors. The pipeline also includes selective mTORC1 inhibitors designed to tip the balance of cellular aging processes and to enhance host immune function. These programs reflect the company’s dual focus on chronic inflammatory diseases and the broader therapeutic potential of modulating immune-related targets.
Founded in 2019 and headquartered in South San Francisco, Rapt Therapeutics operates at the heart of one of the world’s leading biotech hubs. The organization collaborates with academic institutions and strategic partners to accelerate the preclinical and clinical development of its molecules. While much of its research and early-stage trials are conducted in the United States, Rapt’s global vision encompasses partnerships and regulatory filings in multiple regions to broaden patient access.
Rapt Therapeutics is led by President and Chief Executive Officer Paul Hastings, Ph.D., whose career includes senior drug-development roles at leading pharmaceutical firms. The executive team brings together expertise in medicinal chemistry, clinical development, regulatory affairs, and commercialization. Guided by a board of directors with backgrounds in biotech innovation and corporate governance, the company is positioned to translate its scientific insights into new treatment options for patients.
